Device Effectiveness for Femoropopliteal Artery Disease Treatment: Analysis of K-VIS ELLA Registry

Endovascular treatment of lesions in femoropopliteal territory (FPA) has become the main therapeutic option, seeing as it is less invasive and has faster recovery. It has used different devices, such as conventional bare metal stents (BMS), balloon angioplasty (POBA), and drug coated balloons (DCB), as well as drug eluting stents (DES). However, real world data is limited and are seldom well represented in studies. 

Efectividad de los distintos dispositivos para el tratamiento de lesiones femoropopliteas: Análisis del registro K-VIS ELLA

The aim of these Korean multicenter retrospective (2006-2014) and prospective (2010 to now) studies was to compare the efficacy of each of these therapies in the treatment of femoropopliteal lesions in the real world. 

Primary end point was target lesion revascularization (TLR), defined as reintervention within 5mm proximal or distal to the originally treated segment. Secondary end points included loss of patency, major adverse limb events (MALEs) and all cause death.

2,774 limbs were looked at, 826 were treated with POBA, 943 with BMS, 778 with DCB and 227 with DES. Patient mean age was 71 and they were mostly men. Most patients were in Rutherford category 4-6 (41% of patients) and lesions were type C/D according to TASC II (59%). After inverse probability to balance groups, the accumulated incidence of TLR was significantly different between them, with BMS showing the highest incidence (26.5% vs. 25.7% with POBA, 15.9% with DCB and DES). Risk of TLR was significantly lower in the DCB group (HR: 0.44; CI 95%: 0.30-0.64; P < 0.001) or DES (HR: 0.51; CI 95%: 0.29-0.87; P = 0.014) vs. BMS.

Read also: ABSORB IV – Improving Bioresorbable Scaffolds: A Long Road.

There were no differences between DCB and DES patients (P=0.613), or POB vs BMS (P=0.626). As regards MALE risk, when compared against BMS, it resulted lower for DCB (HR: 0.44; 95% CI: 0.30-0.63; P < 0.001) and DES (HR: 0.55; 95% CI: 0.32-0.95; P = 0.030), while POBA did not show differences. This same pattern was observed when looking at patency. There were no differences in all-cause mortality across groups. DCB patients presented favorable results when treating complex FPA lesions (TASCII type C/D) and long segments (>150 mm).

There were no significant differences when comparing DCB vs. DES (P = 0.613) patients, neither when comparing POB vs. BMS (P = 0.626). Also, MALE risk when compared against BMS stenting was lower for DCB (HR: 0.44; CI 95%: 0.30-0.63; P < 0.001) and DES (HR: 0.55; CI 95%: 0.32-0.95; P = 0.030), while POBA patients showed no significant differences. This same pattern was observed when looking at patency. There were no differences in all-cause mortality across groups. The DCB group presented favorable results when treating complex FPA lesions (TASCII type C/D) and long segments (>150 mm).

Conclusion 

This real world registry on FPA lesions showed that the use of DCB and DES was associated to better outcomes vs. POBA or BMS as regards TLR, MALE and patency at 2 years. The use of DCB was superior to BMS in preventing TLR, regardless lesion complexity, while DES superiority over BMS was attenuated in complex lesions. 

Dr. Andrés Rodríguez

Dr. Andrés Rodríguez.
Member of the Editorial Board of SOLACI.org.

Original Title: Device Effectiveness for Femoropopliteal Artery Disease Treatment An Analysis of K-VIS ELLA Registry.

Reference: Seung-Jun Lee, MD et al J Am Coll Cardiol Intv 2023;16:1640–1650.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....

Chronic Thromboembolic Pulmonary Hypertension: Treatment Outcomes According to a Worldwide Registry

Chronic thromboembolic pulmonary hypertension (CTEPH) is a highly limiting condition that, despite its moderate incidence, significantly impacts patient prognosis and quality of life. The...

Contemporary Outcomes of Acute Limb Ischemia Endovascular Revascularization

Acute limb ischemia (ALI) is a vascular emergency with high mortality rate. It has been defined as a sudden occlusion of limb perfusion compromising...

TCT 2024 | SIRONA: Randomized Study Comparing Sirolimus-Coated vs Paclitaxel-Coated Balloon Angioplasty in Femoropopliteal Disease

This prospective, randomized, multicenter, investigator-initiated non-inferiority study compared the use of sirolimus-coated balloon (MagicTouch) vs paclitaxel-coated balloon in endovascular treatment.  The primary objective was to...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Sievers Type 1 Bicuspid Valves: Which to Use?

One of the current challenges in TAVR is bicuspid aortic valves (BAV), because of their anatomical complexity, calcification, raphe presence, aortic dilation and associated...

AHA 2024 | VANISH2 Trial

Cardiac defibrillator implants (CDIs) have been shown to improve survival in patients with ischemic cardiomyopathy and ventricular tachycardia (VT). However, approximately one third of...

AHA 2024 | SUMMIT

It has been previously shown that the pharmacological treatment of obesity (semaglutide) can reduce cardiovascular events in patients with cardiac failure (CF) and preserved...